TY - JOUR
T1 - A Dual-Network Nerve Adhesive with Enhanced Adhesion Strength Promotes Transected Peripheral Nerve Repair
AU - Xue, Wen
AU - Shi, Wen
AU - Kuss, Mitchell
AU - Kong, Yunfan
AU - Alimi, Olawale A.
AU - Wang, Han Jun
AU - DiMaio, Dominick J.
AU - Yu, Cunjiang
AU - Duan, Bin
N1 - Publisher Copyright:
© 2022 The Authors. Advanced Functional Materials published by Wiley-VCH GmbH.
PY - 2023/1/10
Y1 - 2023/1/10
N2 - Peripheral nerve transection has a high prevalence and results in functional loss of affected limbs. The current clinical treatment using suture anastomosis significantly limits nerve recovery due to severe inflammation, secondary damage, and fibrosis. Fibrin glue, a commercial nerve adhesive as an alternative, avoids secondary damage but suffers from poor adhesion strength. To address their limitations, a highly efficacious nerve adhesive based on dual-cross-linking of dopamine-isothiocyanate modified hyaluronic acid and decellularized nerve matrix is reportedr. This dual-network nerve adhesive (DNNA) shows controllable gelation behaviors feasible for surgical applications, robust adhesion strength, and promotes axonal outgrowth in vitro. The in vivo therapeutic efficacy is tested using a rat-based sciatic nerve transection model. The DNNA decreases fibrosis and accelerates axon/myelin debris clearance at 10 days post-surgery, compared to suture and commercial fibrin glue treatments. At 10 weeks post-surgery, the strong adhesion and bioactivity allow DNNA to significantly decrease intraneural inflammation and fibrosis, enhance axon connection and remyelination, aid motor and sensory function recovery, as well as improve muscle contraction, compared to suture and fibrin treatments. Overall, this dual-network hydrogel with robust adhesion provides a rapid and highly efficacious nerve transection treatment to facilitate nerve repair and neuromuscular function recovery.
AB - Peripheral nerve transection has a high prevalence and results in functional loss of affected limbs. The current clinical treatment using suture anastomosis significantly limits nerve recovery due to severe inflammation, secondary damage, and fibrosis. Fibrin glue, a commercial nerve adhesive as an alternative, avoids secondary damage but suffers from poor adhesion strength. To address their limitations, a highly efficacious nerve adhesive based on dual-cross-linking of dopamine-isothiocyanate modified hyaluronic acid and decellularized nerve matrix is reportedr. This dual-network nerve adhesive (DNNA) shows controllable gelation behaviors feasible for surgical applications, robust adhesion strength, and promotes axonal outgrowth in vitro. The in vivo therapeutic efficacy is tested using a rat-based sciatic nerve transection model. The DNNA decreases fibrosis and accelerates axon/myelin debris clearance at 10 days post-surgery, compared to suture and commercial fibrin glue treatments. At 10 weeks post-surgery, the strong adhesion and bioactivity allow DNNA to significantly decrease intraneural inflammation and fibrosis, enhance axon connection and remyelination, aid motor and sensory function recovery, as well as improve muscle contraction, compared to suture and fibrin treatments. Overall, this dual-network hydrogel with robust adhesion provides a rapid and highly efficacious nerve transection treatment to facilitate nerve repair and neuromuscular function recovery.
UR - http://www.scopus.com/inward/record.url?scp=85141462002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141462002&partnerID=8YFLogxK
U2 - 10.1002/adfm.202209971
DO - 10.1002/adfm.202209971
M3 - Article
C2 - 36816838
AN - SCOPUS:85141462002
SN - 1616-301X
VL - 33
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 2
M1 - 2209971
ER -